Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter C Meijers

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Expert Opinion on Pharmacotherapy|April 5, 2017
New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerationsElles M Screever, Wouter C Meijers, Dirk J van Veldhuisen, et al.
Physiological Reviews|September 22, 2025
Forward and reverse cardio-oncologyWouter C Meijers, Joseph Pierre Aboumsallem, Alexander R Lyon, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Galectin-3 and heart failure: prognosis, prediction & clinical utilityMando D Filipe, Wouter C Meijers, A Rogier van der Velde, et al.
European Journal of Heart Failure|July 20, 2019
Cancer and heart disease: associations and relationsRudolf A de Boer, Wouter C Meijers, Peter van der Meer, et al.
Current Heart Failure Reports|April 7, 2026
TIM-3 in Cardiovascular DiseaseLaura I Yousif, Aukje G Sijtema, Margot J Chevalier, et al.
Frontiers in Pharmacology|October 20, 2022
The role of immune checkpoints in cardiovascular diseaseLaura I Yousif, Anniek A Tanja, Rudolf A de Boer, et al.
European Journal of Clinical Investigation|May 17, 2024
Dutch cardio-oncology cohort: Incident cardiovascular disease predisposes to a higher cancer mortality rateYvonne Koop, Laura Yousif, Rudolf A de Boer, et al.
European Journal of Pharmacology|June 24, 2015
Galectin-3 and post-myocardial infarction cardiac remodelingWouter C Meijers, A Rogier van der Velde, Domingo A Pascual-Figal, et al.
European Journal of Pharmacology|November 15, 2024
Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutionsReza Parvan, Joseph Pierre Aboumsallem, Wouter C Meijers, et al.
Heart, Lung & Circulation|February 12, 2025
Cardiotoxicity Beyond Cardiomyocytes-Focus on the Role of Cardiac Fibroblasts and Endothelial CellsYmke Appels, Laura I Yousif, Charlotte S Pieters, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Expert Opinion on Pharmacotherapy|April 5, 2017
New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerationsElles M Screever, Wouter C Meijers, Dirk J van Veldhuisen, et al.
Physiological Reviews|September 22, 2025
Forward and reverse cardio-oncologyWouter C Meijers, Joseph Pierre Aboumsallem, Alexander R Lyon, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Galectin-3 and heart failure: prognosis, prediction & clinical utilityMando D Filipe, Wouter C Meijers, A Rogier van der Velde, et al.
European Journal of Heart Failure|July 20, 2019
Cancer and heart disease: associations and relationsRudolf A de Boer, Wouter C Meijers, Peter van der Meer, et al.
Current Heart Failure Reports|April 7, 2026
TIM-3 in Cardiovascular DiseaseLaura I Yousif, Aukje G Sijtema, Margot J Chevalier, et al.
Frontiers in Pharmacology|October 20, 2022
The role of immune checkpoints in cardiovascular diseaseLaura I Yousif, Anniek A Tanja, Rudolf A de Boer, et al.
European Journal of Clinical Investigation|May 17, 2024
Dutch cardio-oncology cohort: Incident cardiovascular disease predisposes to a higher cancer mortality rateYvonne Koop, Laura Yousif, Rudolf A de Boer, et al.
European Journal of Pharmacology|June 24, 2015
Galectin-3 and post-myocardial infarction cardiac remodelingWouter C Meijers, A Rogier van der Velde, Domingo A Pascual-Figal, et al.
European Journal of Pharmacology|November 15, 2024
Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutionsReza Parvan, Joseph Pierre Aboumsallem, Wouter C Meijers, et al.
Heart, Lung & Circulation|February 12, 2025
Cardiotoxicity Beyond Cardiomyocytes-Focus on the Role of Cardiac Fibroblasts and Endothelial CellsYmke Appels, Laura I Yousif, Charlotte S Pieters, et al.
Pageof 10